NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,168+0.14%BTC$86,421+1.96%VIX15.31−6.59%live tape · as of 03:09 UTC
The Screen · Consumer Defensive · Beverages - Brewers
Anheuser-Busch InBev SA/NV ADR
BUD · the NYSE · USD · Market cap $153.6B · 137,000 employees
Anheuser-Busch InBev SA/NV produces and sells beer in North America, Middle Americas, South America, Europe, the Middle East, Africa, and the Asia Pacific.
FAIL · Does not pass the screen
78.00 USD
Screen close, 2026-09-25 · not a live quote Last reviewed 10 days ago
Screened 2026-09-25 · the tape above runs as of 03:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 78.00 against the desk's fair-value range, base estimate 87.61, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price78.00 USD
Fair value87.61
Ethical score30.0/100
Our investment reviews on this name
2026-07-30Read Distribution81.66-4.5% to today ✓
2026-07-25Read Markup81.66-4.5% to today
2026-07-18Read Distribution82.91-5.9% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Anheuser-Busch InBev SA/NV ADR holds its Distribution at $78.00. The statistical read favours the sellers, held for 47 days.
As held on the ledger · 2026-09-25
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 47 days
Price at the screen
$78.00
Valuation
16.81 trailing · 15.66 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.78
The Workings
Five Screens, Shown in Full
Does not pass. Excluded industry: Beverages - Brewers
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Excluded industry: Beverages - Brewers
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Anheuser-Busch InBev SA/NV does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-25 screen. The gold marker is the market price at the same screen. A 12.3% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +24% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-25 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Beer Giant Brewing Up Ethical Concerns
Anheuser-Busch InBev SA/NV, a global brewer with a portfolio spanning continents, is a titan in the beverage industry. Yet, for investors seeking ethically aligned investments, the company serves up a bitter taste. Despite its expansive reach and a robust 11% annual revenue growth, the stock is currently priced at $77.92, under our fair value of $87.30, offering a 12% margin of safety.
Why it stands out is a bit of a paradox. The company boasts a healthy 15% profit margin and an 11% return on equity, suggesting financial stability and growth. However, its forward P/E of 15.7x aligns with the sector's average, indicating no significant market overvaluation. Yet, our opportunity rating is 'None,' primarily due to Anheuser-Busch InBev's failure on our ethical screen, specifically for operating in the excluded industry of beverage brewing.
Risks here are multifaceted. A narrow moat suggests limited competitive advantage, and while the revenue growth is commendable, the ethical failings overshadow potential gains. The consensus buy rating and a median target of $96 from analysts might entice some, but for those who prioritize ethical investing, the stock's appeal is as flat as day-old beer. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Belgium and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BUD trades on the NYSE (the company is based in Belgium). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution$78.00+0.1%Entry 12
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93.
2026-08-29Distribution$77.92-4.6%Entry 11
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Markup$81.66+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Markup$81.66+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Markup$81.66+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup · changed$81.66+1.4%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Distribution$80.57+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Distribution$80.57-2.8%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$82.91+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it buy, with a mean price target of $93.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
